Budget impact analysis: review of the state of the art

References

• Mauskopf J. Prevalence-based economic evaluation. Value Health1, 251–259 (1998).
   PubMedGoogle Scholar
• Baltussen R, Leidl R, Ament A. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making. PharmacoEconomics16, 449–458 (1999).
   PubMed Web of Science ®Google Scholar
• Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. PharmacoEconomics18, 55–62 (2000).
   PubMed Web of Science ®Google Scholar
• Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics19, 609–621 (2003).
   Web of Science ®Google Scholar
• Koopmanschap MA, Rutten FF. The drug budget silo mentality: the Dutch case. Value Health6(Suppl. 1), S46–S51 (2001).
   Google Scholar
• Fry RN, Avery SG, Sullivan SD. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard – a Foundation for Managed Care Pharmacy Task Force report. Value Health6, 505–521 (2003).
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Drummond M, Brown R, Fendrick AM et al. ISPOR Task Force. Use of pharmacoeconomics information – report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health6, 407–416 (2003).
   PubMed Web of Science ®Google Scholar
• Orlewska D, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health7, 1–10 (2004).
   PubMed Web of Science ®Google Scholar
• NICE. National Institute for Clinical Excellence appraisal of new and existing technologies: interim guidance for manufacturers and sponsors. NICE, London, UK (1999).
   Google Scholar
• Harman RJ. The National Institute for Clinical Excellence. Pharm. J.7073, 869–876 (2001).
   Google Scholar
• Rafferty J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br. Med. J.323, 1300–1303 (1999).
   Google Scholar
• Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inform. J.35, 189–201 (2001).
   Web of Science ®Google Scholar
• Szende A, Mogyorosy Z, Muszbek N, Nagy J, Pallos G, Bozsa C. Methodological guidelines for conducting economic valuation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur. J. Health Econ.3, 196–206 (2002).
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health6, 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Cates SC, Griffin AD. PA pharmacoeconomic model for the treatment of influenza. Pharmacoeconomics16(Suppl. 1), 73–84 (1999).
   PubMed Web of Science ®Google Scholar
• Mauskopf JA. Meeting the NICE requirements: a Markov Model approach. Value Health3, 287–293 (2000).
   PubMedGoogle Scholar
• Nuijten MJC, Rutten F. Combining a budgetary impact analysis and a cost-effectiveness analysis using decision analytic modeling techniques.PharmacoEconomics20, 855–867 (2002).
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Shih T, Baker T et al. Budget impact analysis: combination fluticasone and salmeterol for asthma. Presented at the 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. VA, USA (2004).
   Google Scholar
• Mauskopf J, Sung J, Sendersky V, Baker T. Estimating the budget and health impacts of letrozole for advanced breast cancer. Presented at the 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. VA, USA (2003).
   Google Scholar
• Doyle JJ, Casciano J, Arikian S et al. A multinational pharmacoeconomics evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs, and TCAs. Value Health4, 16–31 (2001).
   PubMedGoogle Scholar
• Tavakoli M. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. PharmacoEconomics21, 443–454 (2003).
   PubMed Web of Science ®Google Scholar
• Zabinski RA, Burke TA, Johnson J et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. PharmacoEconomics19(Suppl. 1), 49–58 (2001).
   PubMedGoogle Scholar
• Dykstra DM, Beronja N, Menges J et al. ESRD managed care demonstration: financial implications. Health Care Financ. Rev.24, 59–75 (2003).
   PubMedGoogle Scholar
• Mason JM, Moayyedi P, Young PJ et al. Population-based and opportunistic screening and eradication of Helicobacter Pylori.Int. J. Tech. Assess.15, 649–660 (1999).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Rapoport AM, Bordini CA et al. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache43, 742–754 (2003).
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Muroff M, Gibson PJ, Grainger D. Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr. Bull.28, 619–635 (2002).
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Tolson JM, Simpson KN et al. Impact of zidovudine-based triple combination therapy on an AIDS Drug Assistance Program. J. AIDS23, 302–313 (2002).
   Web of Science ®Google Scholar
• Grima DT, Burge RT, Becker DL et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T27, 448–455 (2002).
   Google Scholar
• Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J. Managed Care Pharm.9, 150–158 (2000).
   Google Scholar
• Nurnberg HG and Duttagupta S. Economic analysis of sildenafil citrate (Viagra) add-on to treat erectile dysfunction associated with selective serotonin reuptake inhibitor use. Am. J. Therapeutics11, 9–12 (2003).
   Google Scholar
• Simon GE, VonKorff M, Heiligenstein JH et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA275, 1897–1902 (1996).
   PubMed Web of Science ®Google Scholar
• Ozminkowski RJ, Wang S, Marder WD, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. PharmacoEconomics18, 253–264 (2000).
   PubMed Web of Science ®Google Scholar